Innovative Biopharmaceuticals for Infectious Diseases
Oragenics is focused on developing NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 caused by the SARS-CoV-2 virus and its variants.
Learn More About OragenicsFighting Global Bacterial Antibiotic Resistance
Oragenics is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.
Learn More About Lantibiotics
